JUPITER, Fla., September 06, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received full approval from the ...

Since Filspari's trial data suggests it's superior to Irbesartan, its market might be larger in the long run. For context, Irbesartan's market is projected to grow to $2.9 billion by 2031.

FILSPARI REMS: Due to the risk of hepatotoxicity and embryo-fetal toxicity, FILSPARI is available only through a restricted program called the FILSPARI REMS. Prescribers, ...

Six months after Travere Therapeutics’ Filspari won an accelerated nod to treat patients with a rare kidney disease, the first-of-its-kind drug narrowly failed its confirmatory trial. While the ...

Filspari's REMS Program Poses Challenges to Market Adoption and Sales Growth. As I anticipated, the label for Filspari emphasizes the potential risks of hepatotoxicity and embryo-fetal toxicity, ...

Total revenue for Q1 2025 was $81.7 million, including $75.9 million in net product sales. FILSPARI sales accounted for the majority, demonstrating substantial sequential and year-over-year growth.

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and ...

FILSPARI REMS: Due to the risk of hepatotoxicity and embryo-fetal toxicity, FILSPARI is available only through a restricted program called the FILSPARI REMS. Prescribers, ...

FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term durable benefit on ...

So far, Filspari’s launch has been going well. The drug brought in $27.1 million in sales in the second quarter of the year, coming 37% above the prior quarter and ahead of analysts’ consensus ...